Wei Shi

机构：Jiangsu Hengrui Medicine (China) · ORCID：0000-0003-0368-1887

发表论文 103 篇 · 总被引 2097 次 · h-index 26

代表论文

• Helenine blocks NLRP3 activation by disrupting the NEK7-NLRP3 interaction and ameliorates inflammatory diseases (2023 · Phytomedicine · 被引 31)
• Nanobody-based trispecific T cell engager (Nb-TriTE) enhances therapeutic efficacy by overcoming tumor-mediated immunosuppression (2023 · Journal of Hematology & Oncology · 被引 30)
• Tanshinone I specifically suppresses NLRP3 inflammasome activation by disrupting the association of NLRP3 and ASC (2023 · Molecular Medicine · 被引 29)
• Nanobody-based bispecific T-cell engager (Nb-BiTE): a new platform for enhanced T-cell immunotherapy (2023 · Signal Transduction and Targeted Therapy · 被引 28)
• Recent advances of nanobody applications in diagnosis and detection (2023 · MedComm – Biomaterials and Applications · 被引 26)
• Novel role for epalrestat: protecting against NLRP3 inflammasome-driven NASH by targeting aldose reductase (2023 · Journal of Translational Medicine · 被引 24)